tau-临床不匹配识别共病理与认知韧性
该纵向观察队列研究基于ADNI与Penn-ADRC中淀粉样蛋白阳性个体,利用tau-PET或p-tau217与CDR-SB构建tau-临床不匹配模型,分为一致型、韧性型和脆弱型;脆弱型更常见TDP-43和α-突触核蛋白共病理且认知恶化更早,韧性型认知受损更晚,模型可用于预测抗淀粉样蛋白治疗中的个体认知轨迹。
要点
- tau-临床不匹配可分为一致型、韧性型和脆弱型三类。
- 脆弱型更可能携带TDP-43和α-突触核蛋白共病理。
- 该模型有助于个体化预后及监测治疗反应。
核心结论
- tau-临床不匹配可识别因共病理而病程加速的个体及对阿尔茨海默病理表现出认知韧性的个体。
- 该模型为临床提供个体化预后及潜在监测疾病修饰治疗反应的工具。
研究设计与样本
- 纵向观察性队列研究,2004至2024年在美国多个学术医学中心开展,参与ADNI或Penn-ADRC。
- ADNI队列中Aβ+个体998例,纳入365例tau-PET组和524例p-tau217组构建不匹配模型。
- 独立验证集为Penn-ADRC队列中Aβ+个体248例中的244例。
主要发现
- ADNI tau-PET组365例(平均年龄75.4岁,女性192例)中55.6%为一致型、24.7%为韧性型、19.7%为脆弱型。
- ADNI p-tau217组524例(平均年龄77.1岁,男性268例)中57.1%为一致型、23.7%为韧性型、19.3%为脆弱型。
- 脆弱组有TDP-43神经退行性模式及α-突触核蛋白阳性的更大可能性证据。
- 不匹配组临床轨迹分化,脆弱组认知受损更早,韧性个体受损更晚。
- Penn-ADRC独立数据集244例(平均年龄73.7岁,女性139例)中见相似发现。
临床怎么用
- 可利用tau-PET或p-tau217与CDR-SB构建tau-临床不匹配模型,辅助判断共病理风险与认知韧性。
- 对脆弱型个体可加强监测与预后沟通,对韧性型个体避免过度悲观预测。
- 该模型有望用于抗淀粉样蛋白治疗期间个体化认知轨迹预测与疗效监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Even within individuals who are amyloid positive, clinical symptoms can be impacted by Alzheimer pathology, other pathologic proteins, and cognitive reserve or resilience. Understanding how each of these factors contributes to a patient's clinical presentation is crucial for prognosis and treatment decisions in the era of disease-modifying therapies. OBJECTIVE: To evaluate tau-clinical mismatch as a means to identify those more likely to harbor copathology and/or exhibit resilience to Alzheimer pathology. DESIGN, SETTING, AND PARTICIPANTS: This was a longitudinal, observational cohort study conducted from 2004 to 2024. The setting included multiple academic medical centers in the US participating in the Alzheimer's Disease Neuroimaging Initiative (ADNI) or Penn Alzheimer's Disease Research Center (Penn-ADRC). Included in the analysis were individuals with clinical assessment and measures of either tau positron emission tomography (tau-PET) or phosphorylated tau 217 (p-tau217) who were selected from individuals positive for amyloid β (Aβ+) in the ADNI cohort (aged 55-95 years) and the Penn-ADRC cohort (aged 54-92 years). EXPOSURES: Clinical assessment (Clinical Dementia Rating Sum of Boxes [CDR-SB]) and tau burden (tau-PET or p-tau217) for mismatch group classification. MAIN OUTCOMES AND MEASURES: Cross-sectional measures of neurodegeneration (medial temporal lobe volume and thickness, cortical thickness, TAR DNA-binding protein 43 [TDP-43] imaging signature), α-synuclein cerebrospinal fluid seed-amplification assay, and longitudinal CDR-SB. RESULTS: A total of 365 participants (mean [SD] age, 75.4 [7.9] years; 192 female [52.6%]) in the ADNI tau-PET group and 524 participants (mean [SD] age, 77.1 [7.9] years; 268 male [51.1%]) in the ADNI p-tau217 group were selected from the 998 individuals who were Aβ+ in the ADNI cohort and used to generate tau-clinical mismatch models with 55.6% to 57.1% classified as canonical (CDR-SB commensurate to tau), 23.7% to 24.7% as resilient (CDR-SB < tau), and 19.3% to 19.7% as vulnerable (CDR-SB > tau). Vulnerable groups had evidence of greater likelihood of copathology, with TDP-43 neurodegeneration patterns and α-synuclein positivity. Mismatch groups showed diverging clinical trajectories with earlier cognitive impairment in vulnerable groups and later impairment in resilient individuals. Similar findings were seen when applied to an independent dataset of 244 individuals (mean [SD] age, 73.7 [6.8] years; 139 female [57.0%]) of the 248 who were Aβ+ in Penn-ADRC cohort. Finally, these models were applied to a cohort receiving antiamyloid therapy to show the utility of this method for predicting individual cognitive trajectories during therapy. CONCLUSION AND RELEVANCE: Results of this cohort study suggest that tau-clinical mismatch identified individuals more likely to have an accelerated disease course due to the presence of copathology and those exhibiting greater cognitive resilience to disease pathology. These models provide an important tool that can be implemented in clinical practice to provide improved individualized prognosis and, potentially, monitoring of response to disease-modifying therapy.
引用
- Brown CA, Mundada NS, Cousins KAQ, et al. Evaluation of Copathology and Clinical Trajectories in Individuals With Tau-Clinical Mismatch. JAMA Neurol. 2026. PMID: 41396614. doi:10.1001/jamaneurol.2025.4974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。